Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 15/20 | 0.60 |
| ▸ | CCNB1 | P14635 | 15/20 | 0.60 |
| ▸ | CDK2 | P24941 | 14/20 | 0.60 |
| ▸ | CCNA2 | P20248 | 13/20 | 0.60 |
| ▸ | CCNA1 | P78396 | 13/20 | 0.60 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.51 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | MGMT | P16455 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL880169 | 0.92 | CDK1 (0.61) | CDK1CCNB1CDK2CCNA2CCNA1 | |
| SCHEMBL8618497 | 0.87 | CDK1 (0.44) | CDK1CCNB1CDK2CCNA2CCNA1 | |
| SCHEMBL8537496 | 0.86 | CDK1 (0.44) | CDK1CCNB1CDK2CCNA2CCNA1 | |
| SCHEMBL6925964 | 0.85 | CDK1 (0.43) | CDK1CCNB1CDK2CCNA2CCNA1 | |
| SCHEMBL12227596 | 0.84 | CDK1 (0.42) | CDK1CCNB1CDK2CCNA2CCNA1 | |
| SCHEMBL16357819 | 0.83 | PIN1 (0.50) | CDK1CCNB1CDK2CCNA2CCNA1 | |
| Methylguanine SCHEMBL1336757 | 0.80 | CDK1 (0.41) | CDK1CCNB1CDK2CCNA2CCNA1 | |
| Methylguanine SCHEMBL29968306 | 0.80 | CDK1 (0.41) | CDK1CCNB1CDK2CCNA2CCNA1 | |
| 6-Chloroguanine SCHEMBL17187923 | 0.80 | CDK1 (0.39) | CDK1CCNB1CDK2CCNA2CCNA1 | |
| SCHEMBL821881 | 0.80 | CDK1 (0.46) | CDK1CCNB1CDK2CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145417-B2 | Optical performance humidity dependency improving agent for cellulose acylate film | FUJIFILM CORPORATION (JP) | 2015-09-29 | — | — | US | disclosed |
| US-9145417-B2 | Optical performance humidity dependency improving agent for cellulose acylate film | FUJIFILM CORPORATION (JP) | 2015-09-29 | — | — | US | disclosed |
| US-20110262661-A1 | Optical performance humidity dependency improving agent for cellulose acylate film | FUJIFILM CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110262661-A1 | Optical performance humidity dependency improving agent for cellulose acylate film | FUJIFILM CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| US-5637574-A | VIRICIDES | GLAXO WELLCOME INC. (US) | 1997-06-10 | — | — | US | disclosed |
| EP-0417999-B1 | Antiviral compounds | WELLCOME FOUND (GB) | 1996-03-13 | — | — | EP | disclosed |
| EP-0671410-A1 | Antiviral compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-09-13 | — | — | EP | disclosed |
| US-5420115-A | Method for the treatment of protoza infections with 21 -deoxy-21 -fluoropurine nucleosides | BURROUGHS WELLCOME CO. (US) | 1995-05-30 | — | — | US | disclosed |
| EP-0620734-A1 | THERAPEUTIC NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-10-26 | — | — | EP | disclosed |
| WO-1993013778-A1 | THERAPEUTIC NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-07-22 | — | — | WO | disclosed |
| US-5153318-A | Viricides for hepatitis and human t-cell leukemia/lymphoma viruses | BURROUGHS WELLCOME CO. (US) | 1992-10-06 | — | — | US | disclosed |
| EP-0421739-A1 | 3'-azido purine nucleoside | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-04-10 | — | — | EP | disclosed |
| EP-0417999-A1 | Antiviral compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262661-A1 | Optical performance humidity dependency improving agent for cellulose acylate film | ALKBH1, ACOT7, ALKBH2 | CDK1 3407/4885CCNB1 2736/4885CDK2 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.